Neurocrine Biosciences (NBIX) Profit After Tax Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 67.73% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.33% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1,682.88% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | -212.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,682.88% |
| Dec 31, 2025 | 70.55% |
| Sep 30, 2025 | 61.94% |
| Jun 30, 2025 | 65.38% |
| Mar 31, 2025 | -72.04% |
| Dec 31, 2024 | -41.94% |
| Sep 30, 2024 | 57.33% |
| Jun 30, 2024 | -31.94% |
| Mar 31, 2024 | 151.83% |
| Dec 31, 2023 | 89.73% |
| Sep 30, 2023 | 20.44% |
| Jun 30, 2023 | 582.32% |
| Mar 31, 2023 | -651.08% |
| Dec 31, 2022 | 1,552.54% |
| Sep 30, 2022 | 204.44% |
| Jun 30, 2022 | -146.81% |
| Mar 31, 2022 | -56.70% |
| Dec 31, 2021 | -101.70% |
| Sep 30, 2021 | 138.14% |
| Jun 30, 2021 | -46.86% |